User:Mr. Ibrahem/Repaglinide

Mr. Ibrahem/Repaglinide
Clinical data
Trade names	Prandin, GlucoNorm, NovoNorm, Enyglid, others
AHFS/Drugs.com	Monograph
MedlinePlus	a600010
License data	EU EMA: by INN; US DailyMed: Repaglinide; US FDA: Prandin;
Pregnancy; category	AU: C; ;
Routes of; administration	By mouth
Drug class	Meglitinide
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	56% (by mouth)
Protein binding	>98%
Metabolism	Liver oxidation and glucuronidation (CYP3A4-mediated)
Elimination half-life	1 hour
Excretion	Fecal (90%) and kidney (8%)
Identifiers
	IUPAC name (S)-(+)-2-ethoxy-4-[2-(3-methyl-1-[2-(piperidin-1-yl)phenyl]butylamino)-2-oxoethyl]benzoic acid;
Chemical and physical data
Formula	C27H36N2O4
Molar mass	452.595 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	126 to 128 °C (259 to 262 °F)
	SMILES O=C(O)c1ccc(cc1OCC)CC(=O)N[C@H](c2ccccc2N3CCCCC3)CC(C)C;
	InChI InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1 ; Key:FAEKWTJYAYMJKF-QHCPKHFHSA-N ;
	(verify)

Repaglinide, sold under the brand name Prandin among others, is a medication used to control blood sugar in type 2 diabetes.^[2] It is used together with diet and exercise.^[2] It is taken by mouth.^[2] Maximum effects occur in about 3 hours.^[1]

Common side effects include low blood sugar, headache, joint pain, nausea, and back pain.^[2] Use in pregnancy is not generally recommended.^[1] It is in the meglitinide class of medication and works by promoting insulin release from the pancreas in response to blood sugar.^[1]

Repaglinide was developed in 1983 and approved for medical use in the United States in 1997.^[2]^[3] It is available as a generic medication.^[4] In the United Kingdom a month of medication costs around £5 as of 2021.^[4] This amount in the United States is about 25 USD.^[5]

References[edit]

^ ^a ^b ^c ^d "Repaglinide Monograph for Professionals". Drugs.com. Archived from the original on 17 May 2021. Retrieved 16 October 2021.
^ ^a ^b ^c ^d ^e ^f ^g ^h "DailyMed - REPAGLINIDE - repaglinide tablet". dailymed.nlm.nih.gov. Archived from the original on 2015-10-19. Retrieved 2015-11-04.
^ Engel, Jürgen; Kleemann, Axel; Kutscher, Bernhard; Reichert, Dietmar (14 May 2014). Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. Georg Thieme Verlag. p. 1199. ISBN 978-3-13-179275-4. Archived from the original on 17 October 2021. Retrieved 16 October 2021.
^ ^a ^b BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 740. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
^ "Repaglinide Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 6 August 2020. Retrieved 16 October 2021.

[AHFS2021-1] "Repaglinide Monograph for Professionals". Drugs.com. Archived from the original on 17 May 2021. Retrieved 16 October 2021.

[PI2021-2] ^ ^a ^b ^c ^d ^e ^f ^g ^h "DailyMed - REPAGLINIDE - repaglinide tablet". dailymed.nlm.nih.gov. Archived from the original on 2015-10-19. Retrieved 2015-11-04.

[3] Engel, Jürgen; Kleemann, Axel; Kutscher, Bernhard; Reichert, Dietmar (14 May 2014). Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. Georg Thieme Verlag. p. 1199. ISBN 978-3-13-179275-4. Archived from the original on 17 October 2021. Retrieved 16 October 2021.

[BNF80-4] BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 740. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[5] "Repaglinide Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 6 August 2020. Retrieved 16 October 2021.

[1]

[2]

[3]

[4]

[5]